Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

JA Bernstein; JC Virchow; K Murphy; JF Maspero; J Jacobs; Y Adir; M Humbert; M Castro; DA Marsteller; J McElhattan; L Hickey; M Garin; R Vanlandingham; Guy Brusselle

doi:10.1016/s2213-2600(19)30372-8

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

JA Bernstein, JC Virchow, K Murphy, JF Maspero, J Jacobs, Y Adir, M Humbert, M Castro, DA Marsteller, J McElhattan, L Hickey, M Garin, R Vanlandingham, Guy Brusselle

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

Original language	English
Pages (from-to)	461-474
Number of pages	14
Journal	The Lancet Respiratory Medicine
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/s2213-2600(19)30372-8
Publication status	Published - 2020

Access to Document

10.1016/s2213-2600(19)30372-8

Cite this

Bernstein, JA., Virchow, JC., Murphy, K., Maspero, JF., Jacobs, J., Adir, Y., Humbert, M., Castro, M., Marsteller, DA., McElhattan, J., Hickey, L., Garin, M., Vanlandingham, R., & Brusselle, G. (2020). Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. The Lancet Respiratory Medicine, 8(5), 461-474. https://doi.org/10.1016/s2213-2600(19)30372-8

Bernstein, JA ; Virchow, JC ; Murphy, K et al. / Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. In: The Lancet Respiratory Medicine. 2020 ; Vol. 8, No. 5. pp. 461-474.

@article{36e2f4e9864d46a2bf0e50b39bf46249,

title = "Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials",

author = "JA Bernstein and JC Virchow and K Murphy and JF Maspero and J Jacobs and Y Adir and M Humbert and M Castro and DA Marsteller and J McElhattan and L Hickey and M Garin and R Vanlandingham and Guy Brusselle",

year = "2020",

doi = "10.1016/s2213-2600(19)30372-8",

language = "English",

volume = "8",

pages = "461--474",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd.",

number = "5",

}

Bernstein, JA, Virchow, JC, Murphy, K, Maspero, JF, Jacobs, J, Adir, Y, Humbert, M, Castro, M, Marsteller, DA, McElhattan, J, Hickey, L, Garin, M, Vanlandingham, R & Brusselle, G 2020, 'Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials', The Lancet Respiratory Medicine, vol. 8, no. 5, pp. 461-474. https://doi.org/10.1016/s2213-2600(19)30372-8

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. / Bernstein, JA; Virchow, JC; Murphy, K et al.

In: The Lancet Respiratory Medicine, Vol. 8, No. 5, 2020, p. 461-474.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

AU - Bernstein, JA

AU - Virchow, JC

AU - Murphy, K

AU - Maspero, JF

AU - Jacobs, J

AU - Adir, Y

AU - Humbert, M

AU - Castro, M

AU - Marsteller, DA

AU - McElhattan, J

AU - Hickey, L

AU - Garin, M

AU - Vanlandingham, R

AU - Brusselle, Guy

PY - 2020

Y1 - 2020

U2 - 10.1016/s2213-2600(19)30372-8

DO - 10.1016/s2213-2600(19)30372-8

M3 - Article

VL - 8

SP - 461

EP - 474

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 5

ER -

Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. The Lancet Respiratory Medicine. 2020;8(5):461-474. doi: 10.1016/s2213-2600(19)30372-8